FilingReader Intelligence
Alphamab Oncology forecasts turnaround to profit
August 13, 2025 at 05:01 PM UTC•By FilingReader AI
Alphamab Oncology expects a net profit of at least RMB20.0 million for the six months ended June 30, 2025, compared with a RMB44.9 million loss in the same period of 2024.
The turnaround is primarily attributed to milestone revenue from three licensed collaborations and sales from its commercialized product.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:9966•Hong Kong Exchange
News Alerts
Get instant email alerts when Alphamab Oncology publishes news
Free account required • Unsubscribe anytime